Subject:
A.M.A.S. test for Cancer
Resent-Date:
Fri, 15 Jan 1999 05:41:29 -0800
Resent-From:
rife-list@eskimo.com
Date:
Fri, 15 Jan 1999 08:40:41 EST
From:
DrJastram@aol.com
To:
rife-list@eskimo.com

Good Morning List!
I would wager that the medics involved with the selling of the 'preventive'
bilateral mastectomies did not mention the following information. We used this
test to determine whether or not Terry had been successful in eliminating her
five melanomas this summer past. She was. Her test results helped insulate her
from the fear that others, including family members, attempted to instill in
her to go see a medic and get carved on like the Christmas goose.

>From Terry:
Cutting off a woman's healthy breasts in order to prevent breast cancer
is extremely heavy-handed.
However, if it is the intention of the doctor to provide relief from the fear
of cancer, there is a MUCH less invasive alternative: the AMAS test (Anti-
malignan Antibody Screening).
Here is a question:
If a woman at high risk of developing breast cancer were given the choice
between amputation of her breasts, or having a $135 blood test that will
accurately determine if she has any malignancy in any part of her body,
what do you think she will choose?
If she were REALLY worried, she could repeat the AMAS test every year or so,
instead of exposing herself to numerous mammograms or other invasive
procedures.

Respectfully yours,
Terry Jastram
Ned Jastram, D.C.

The following article is more definitve:

The AMAS Test (Anti-Malignin Antibody in Serum)
by Steven D. Edelston, M.D.
In 1974, Dr. Samuel Bogash (MD, Ph.D.) discovered a new antigen located
on all cancer cells. He and his researcher / wife, Eleanor Bogash, MD, founded
Oncolab to do this test for research and later clinical purposes.

Dr. Bogash is a Harvard-trained research neurochemist. He discovered
that the outer coating on cancer cells contain sugar molecules
over an inner layer of protein (glycoproteins). Cancer cells bump
into each other and the outer layer is ground off-exposing the inner protein
layer and the malignin antigen.

It took Drs. Bogash seven years to determine that the antigen was on all
cancer cells, not just brain cancer which they were originally studying.

Due to cell recognition, our immune system spots Malignin. When it sees this
foreign protein it produces antibodies to destroy it-Anti-malignin antibodies.
This is what is measured in the study; it is our body's defense against
cancer. By 1988, Dr. Bogash showed that the anti-malignin antibody killed
cancer cells in the test tube.

Greater than 95% of patients with cancer have AMAS levels above 135. AMAS
levels below 135 are seen in normal individuals who do not have cancer.
Sometimes there is doubt about the test (borderline numbers) and at these
times the test needs to be repeated and followed up at certain intervals.

Normal levels of AMAS are seen in successfully treated cancer patients and in
patients who never had cancer. Cases of advanced or terminal cancer may also
have normal levels or even very low normal. The clinical status of the patient
must be correlated with the AMAS test result.

The test is patented and the FDA has approved it. The test is available
for use in several areas related to cancer:

1.Cancer Screening Test. Today a check-up in your physician's office
includes a history, a physical examination and selected laboratory tests aimed
at detecting potential problems including cancer. It will now include an AMAS
test, and thus might defer using a chest X-ray, proctoscope, CT scan, pap
smear, and even mammography. These cancer screens will not be needed unless
the AMAS test is abnormal.

2.A Cancer Monitoring Test. After cancer has been treated both the patient
and the doctor want to know if the cancer has been cured or
if some malignant cells are still in the body. The AMAS test can answer this
dilemma. If there is cancer present, the AMAS test remains elevated.

3.In Differential Diagnosis. At times a shadow on a chest X-ray or
a spot in the liver or kidney on a CT scan are suspicious for cancer
and only a biopsy can tell. That is an invasive procedure. The AMAS test can
tell you if the tissue is malignant. If the AMAS is normal,
the lesion in question is not a cancer.

To date, over 1000 patients with breast cancer have been studied using the
AMAS test. It has been used to tell if the cancer has been cured.
New data suggests that the breast cancer cannot be said to be
in remission unless the AMAS test returns to normal. AMAS has found breast
cancer as small as a pencil dot long before a mammogram
can show it.

The AMAS detects all common cancers and the uncommon ones too.
Studies on more than 6000 patients show the sensitivity of AMAS to be greater
than 95%. The false positive rate and false negative rates are about 1% of
the total, making the specificity about 99%.

Contact info for those interested:
Oncolab
36 The Fenway
Boston, MA 02215
Tel = 800 922- 8378